The Tumor Suppressive Reagent Taurolidine Inhibits Growth of Malignant Melanoma-a Mouse Model

Journal of Surgical Research

Volumn 143, Issue 2, 2007, Pages 372-378

  Braumann, Chris ^a   Jacobi, Christoph A ^a   Rogalla, Stephan ^a   Menenakos, Charalambos ^a   Fuehrer, Kirsten ^a   Trefzer, Uwe ^a   Hofmann, Maja ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

intraperitoneal; intravenous; malignant melanoma; mice; taurolidine

Indexed keywords

RINGER SOLUTION; TAUROLIDINE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; LAPAROTOMY; MELANOMA; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; SOFT TISSUE NEOPLASMS; SUBCUTANEOUS TISSUE; TAURINE; THIADIAZINES;

EID: 36049039232     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2007.01.041     Document Type: Article

References (33)

1. Pfirrmann R.W. Taurolin in der Anwendung bei chirurgischen Infektionen. Chir Gastroenterol (1991) 131
2. Jurewitsch B., and Jeejeebhoy K.N. Taurolidine lock: The key to prevention of recurrent catheter-related bloodstream infections. Clin Nutr 24 (2005) 462
3. Koldehoff M., and Zakrzewski J.L. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents 24 (2004) 491
4. McCourt M., Wang J.H., Sookhai S., et al. Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol 7 (2000) 685
5. Jacobi C.A., Peter F.J., Wenger F.A., et al. New therapeutic strategies to avoid intra- and extraperitoneal metastases during laparoscopy: results of a tumor model in the rat. Dig Surg 16 (1999) 393
6. Braumann C., Ordemann J., Wildbrett P., et al. Influence of intraperitoneal and systemic application of taurolidine and taurolidine/heparin during laparoscopy on intraperitoneal and subcutaneous tumor growth in rats. Clin Exp Metastasis 18 (2000) 547
7. Braumann C., Ordemann J., Kilian M., et al. Local and systemic chemotherapy with taurolidine and taurolidine/heparin in colon cancer-bearing rats undergoing laparotomy. Clin Exp Metastasis 20 (2003) 387
8. Darnowski J.W., Goulette F.A., Cousens L.P., et al. Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer. Cancer Chemother Pharmacol 54 (2004) 249
9. Nici L., Monfils B., and Calabresi P. The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. Clin Cancer Res 10 (2004) 7655
10. Shrayer D.P., Lukoff H., King T., et al. The effect of taurolidine on adherent and floating subpopulations of melanoma cells. Anticancer Drugs 14 (2003) 295-303
11. Wenger F.A., Kilian M., Braumann C., et al. Effects of taurolidine and octreotide on port site and liver metastasis after laparoscopy in an animal model of pancreatic cancer. Clin Exp Metastasis 19 (2002) 169
12. Volz J., Volz-Koster S., Kanis S., et al. Modulation of tumor-induced lethality after pneumoperitoneum in a mouse model. Cancer 89 (2000) 262
13. Braumann C., Schoenbeck M., Menenakos C., et al. Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats. Clin Exp Metastasis 22 (2005) 77
14. Braumann C., Winkler G., Rogalla P., et al. Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case. World J Surg Oncol 4 (2006) 34
15. O'Brien G.C., Cahill R.A., Bouchier-Hayes D.J., et al. Coimmunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma. Ir J Med Sci 175 (2006) 10
16. Giblin A.V., and Thomas J.M. Incidence, mortality, and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg 60 (2007) 32
17. Haraguchi M., Yamashiro S., Yamamoto A., et al. Isolation of GD3 synthase gene by expression cloning of GM3 alpha-2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody. Proc Natl Acad Sci USA 91 (1994) 10455
18. Workman P., Balmain A., Hickman J.A., et al. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim 22 (1988) 195
19. Becker J.C., Varki N., Gillies S.D., et al. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 98 (1996) 2801
20. Lasithiotakis K.G., Leiter U., Gorkievicz R., et al. The incidence and mortality of cutaneous melanoma in southern Germany: Trends by anatomic site and pathologic characteristics, 1976 to 2003. Cancer 107 (2006) 1331
21. Landis S.H., Murray T., Bolden S., et al. Cancer statistics, 1999. CA Cancer J Clin 49 (1999) 8
22. Thompson J.F., Scolyer R.A., and Kefford R.F. Cutaneous melanoma. Lancet 365 (2005) 687
23. Gandini S., Sera F., Cattaruzza M.S., et al. Meta-analysis of risk factors for cutaneous melanoma. III. Family history, actinic damage, and phenotypic factors. Eur J Cancer 41 (2005) 2040
24. Ries J., Eisner M.P., Kosary C.L., et al. SEER Cancer Statistics Review. Nat Cancer Inst (2002)
25. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19 (2001) 3622-3634
26. Eigentler T.K., and Garbe C. Malignant melanoma: Classification and staging of malignant melanoma. Front Radiat Ther Oncol 39 (2006) 149
27. Guerry D., and Schuchter L.M. Disseminated melanoma-is there a new standard therapy?. N Engl J Med 20 (1992) 560
28. Da Costa M.L., Redmond H.P., and Bouchier-Hayes D.J. Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery. J Surg Res 101 (2001) 111
29. Jacobi C.A., Menenakos C., and Braumann C. Taurolidine-a new drug with antitumor and antiangiogenic effects. Anticancer Drugs 16 (2005) 917
30. Han Z., Ribbizi I., Pantazis P., et al. The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism. Anticancer Res 22 (2002) 1959
31. Braumann C., Henke W., Jacobi C.A., et al. The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis. Int J Cancer 112 (2004) 225
32. Braumann C., Stuhldreier B., Bobrich E., et al. High doses of taurolidine inhibit advanced intraperitoneal tumor growth in rats. J Surg Res 129 (2005) 129
33. Lanfrancone L., Boraschi D., Ghiara P., et al. Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor [CSF], granulocyte-monocyte-CSF, macrophage-CSF, interleukin-1 [IL-1], and IL-6) and are activated and stimulated to grow by IL-1. Blood 80 (1992) 2835